Neihulizumab

N/A

Report date: 2026/03/23 20:03:44

Base Information

Drug NameNeihulizumab
Drug Alias NameAntibody-168AbGn-168AbGn-168HALTB-168
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionApoptosis stimulantsP-selectin glycoprotein ligand-1 agonists
TargetsP-selectin glycoprotein ligand-1
Therapy Area/IndicationsPlaque psoriasisGraft vs Host DiseasePsoriasis +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesPuerto RicoGermany
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesAltrubio Inc
China Registration ClassN/A

Develop Information

Active CompaniesAltrubio Inc
Inactive CompaniesC.H. Boehringer Sohn Ag & Co. KgAbgenomics B.V Taiwan Branch
Active IndicationsGraft vs Host Disease
Inactive IndicationsPlaque psoriasisPsoriasisColitis, Ulcerative +[4] 

Other Information

ATC CodeN/A
Related LinksN/A